CRB-913

Phase 1Small molecule

CCorbus Pharmaceuticals Inc.

CRB-913 is one of 32 small molecule programs targeting Obesity. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ObesityActive, not recruiting

ObesityPhase 1

Active, not recruiting

Competition

Competitive Landscape

392 competitors in Obesity

#DrugCompanyPhaseTrials

Actemra

Roche

Preclinical

2 2

Avapro

Sanofi

Preclinical

1 3

Amidate

Adenocard

Colcrys

Alnylam Pharmaceuticals

Activella

Calciferol

Alnylam Pharmaceuticals

Preclinical

—8

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 9

Prometrium

Ferring

Preclinical

1 10

EGRIFTA WR

TTheratechnologies

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Obesity

NCT07310901

Clinical

Trials by Indication[1]

Obesity1 trial

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

Recruiting·CCorbus Pharmaceuticals Inc.·Phase 1·NCT07310901·252 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CRB-913. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CRB-913 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CRB-913. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Corbus Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCorbus Pharmaceuticals Inc.

CRB-913

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Obesity1 trial

References

Drug Info

Quick Facts

Related News